PMID- 24328935
OWN - NLM
STAT- MEDLINE
DCOM- 20140728
LR  - 20131216
IS  - 1557-8976 (Electronic)
IS  - 0882-8245 (Linking)
VI  - 26
IP  - 6
DP  - 2013 Dec
TI  - Positive inductive effect of swine interleukin-4 on immune responses elicited by 
      modified live porcine reproductive and respiratory syndrome virus (PRRSV) 
      vaccine.
PG  - 404-14
LID - 10.1089/vim.2013.0040 [doi]
AB  - Porcine reproductive and respiratory syndrome (PRRS) has become one of the most 
      economically important diseases to the global pork industry. Currently, the 
      efficacies of available commercial vaccines remain questionable: the modified 
      live-PRRSV vaccines (MLVs) were generally effective but variable in sufficient 
      protection, and the outcomes of inactivated-PRRSV vaccines (IVs) in the field 
      were not very promising. In the present study, we investigated the effect of 
      swine interleukin 4 (IL-4) on the development of virus-specific immune responses 
      elicited by an MLV. The antibody titer against PRRSV membrane proteins in pigs 
      elicited by MLV plus recombinant plasmid encoding IL-4 (group 3) was 
      significantly higher than those elicited by MLV alone (group 1) and MLV plus 
      empty plasmid (group 2) from 35 days post-inoculation (dpi). Similarly, the 
      neutralizing efficacy of sera from group 3 was markedly enhanced compared with 
      group 1 and group 2. In cellular immunity, the ratio of CD3(+)CD4(+)/CD3(+)CD8(+) T 
      lymphocyte subpopulations from group 3 monitored by flow cytometry (FCM) was 
      significantly higher than those from group 1 and group 2 from 42 dpi to 21 days 
      post-challenge (dpc). After viral challenge, pigs in group 3 showed significantly 
      lower virus loads in peripheral blood measured by a real-time quantitative PCR 
      (RT-qPCR), as compared with those in group 1 and group 2. Pigs in group 1 and 
      group 2 had a low fever and displayed mild inappetence, lethargy, rough hair 
      coats, and no lung lesions, while those in group 3 showed almost no clinical 
      signs, no lung lesions. The scores of clinical signs of pigs in group 3 were 
      significantly lower than those in both group 1 and group 2. Interestingly, the 
      scores of lung lesions showed no significant differences among the three groups. 
      Our results indicate that swine IL-4 markedly enhanced the protective immune 
      response of pigs and improved the efficacy of the MLV in preventing PRRS disease.
FAU - Peng, Jun
AU  - Peng J
AD  - 1 College of Veterinary Medicine, Shandong Agricultural University , Taian, China 
      .
FAU - Wang, Jinbao
AU  - Wang J
FAU - Wu, Jiaqiang
AU  - Wu J
FAU - Du, Yijun
AU  - Du Y
FAU - Li, Jun
AU  - Li J
FAU - Guo, Zhongkun
AU  - Guo Z
FAU - Yu, Jiang
AU  - Yu J
FAU - Xu, Shaojian
AU  - Xu S
FAU - Zhang, Yuyu
AU  - Zhang Y
FAU - Sun, Wenbo
AU  - Sun W
FAU - Cong, Xiaoyan
AU  - Cong X
FAU - Shi, Jianli
AU  - Shi J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Viral Immunol
JT  - Viral immunology
JID - 8801552
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Viral Vaccines)
RN  - 207137-56-2 (Interleukin-4)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage/genetics/*pharmacology
MH  - Animals
MH  - Antibodies, Neutralizing/blood
MH  - Antibodies, Viral/blood
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Flow Cytometry
MH  - Interleukin-4/*administration & dosage/genetics/*pharmacology
MH  - Plasmids/administration & dosage
MH  - Porcine Reproductive and Respiratory Syndrome/pathology/prevention & 
      control/virology
MH  - Porcine respiratory and reproductive syndrome virus/*immunology
MH  - Severity of Illness Index
MH  - Swine
MH  - T-Lymphocyte Subsets/immunology
MH  - Vaccines, Attenuated/administration & dosage/immunology
MH  - Viral Load
MH  - Viral Vaccines/*administration & dosage/*immunology
MH  - Viremia/prevention & control
EDAT- 2013/12/18 06:00
MHDA- 2014/07/30 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/07/30 06:00 [medline]
AID - 10.1089/vim.2013.0040 [doi]
PST - ppublish
SO  - Viral Immunol. 2013 Dec;26(6):404-14. doi: 10.1089/vim.2013.0040.